Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute, Inc. (Nasdaq: RZLT) announced positive topline results from its Phase 1a clinical study of RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema (DME). The study showed that RZ402's single dose led to plasma concentrations significantly exceeding target levels, supporting the advancement to a Phase 1b study. The drug was generally safe and well-tolerated, with no serious adverse events reported. The results suggest RZ402 could provide an effective treatment option for DME patients, offering improved delivery and compliance.
Rezolute has secured a $30 million debt financing agreement with SLR Capital Partners to enhance its funding capabilities for advancing targeted therapies for rare and metabolic diseases. The initial $15 million was funded upon closing, with an interest-only period lasting 24 months. The remaining funds may be accessed upon meeting specific milestones. CEO Nevan Elam highlighted that this facility provides non-dilutive operational flexibility as they progress their pipeline, including lead candidate RZ358, currently in Phase 2b development.
Rezolute, Inc. (RZLT) announced positive results from its Phase 2a study of RZ358 for post-gastric bypass hypoglycemia at ENDO 2021. The study demonstrated a significant over 50% improvement in hypoglycemia, achieving near-normal glucose levels. RZ358 was safe, well-tolerated, and did not induce hyperglycemia. The pharmacokinetic model supports the potential effectiveness of RZ358 in future trials, including those for congenital hyperinsulinism. Rezolute is advancing RZ358, which has received Orphan Drug Designation in multiple regions.
Rezolute, Inc. (Nasdaq: RZLT) has appointed Dr. Vlad Hogenhuis and Dr. Nerissa C. Kreher to its Board of Directors as the company advances its lead candidate, RZ358, through late-stage clinical trials for congenital hyperinsulinism.
Dr. Hogenhuis brings extensive experience in rare diseases and has held significant roles in global pharmaceutical companies. Dr. Kreher has a robust background in clinical development within the biotech sector. Their expertise is expected to enhance Rezolute's growth as it continues to develop therapies for rare metabolic disorders.
Rezolute, Inc. (Nasdaq: RZLT) announced CEO Nevan Charles Elam will present at two upcoming virtual investor conferences. The first is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 4:00 p.m. ET. The second is the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. Webcasts will be accessible on the conference portals. Rezolute is advancing therapies for rare diseases, focusing on RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. For details, visit their website.
Rezolute, Inc. (RZLT) reported a net loss of $7.1 million, or $0.88 per share, for Q2 FY2021, an increase from a loss of $6.7 million, or $1.14 per share, in Q2 FY2020. Cash and cash equivalents were $37.0 million as of December 31, 2020, bolstered by $37.5 million from an October 2020 financing round. The ongoing Phase 2b study of RZ358 for congenital hyperinsulinism is enrolling patients, with results expected in H2 2021. Additionally, Rezolute initiated a Phase 1 study of RZ402 in January 2021, targeting diabetic macular edema, with completion anticipated in H1 2021.
Rezolute (RZLT) has initiated dosing in a Phase 1 clinical trial for RZ402, an oral plasma kallikrein inhibitor targeting diabetic macular edema (DME). This trial (RZ402-101) aims to assess safety, tolerability, and pharmacokinetics in healthy adults, with completion expected in early 2021. This milestone expands Rezolute's pipeline, reinforcing its commitment to novel therapies for serious metabolic diseases. RZ402's oral administration could optimize treatment outcomes for DME, where current therapies face compliance challenges.
Rezolute, Inc. (Nasdaq:RZLT) announced the appointment of IssuerDirect as its new registrar, transfer agent, and shareholder support provider, replacing VStock Transfer, LLC. This transition requires no action from shareholders. Rezolute is focused on developing therapies for rare and metabolic diseases, with its lead asset, RZ358, in Phase 2b for treating congenital hyperinsulinism. Another pipeline drug, RZ402, is an oral plasma kallikrein inhibitor, set to enter clinical development for diabetic macular edema.
Rezolute, Inc. (Nasdaq:RZLT) announced the FDA's clearance of an Investigational New Drug (IND) application for RZ402, an orally available plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). A Phase 1 clinical study is expected to start in Q1 2021. RZ402 has demonstrated over 80% reduction in retinal inflammation and vascular leakage in preclinical rodent models, with a favorable safety profile. This drug aims to address current treatment limitations by providing an effective oral alternative for DME, enhancing patient compliance.
Rezolute, Inc. (Nasdaq:RZLT) will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020. CEO Nevan Charles Elam will lead the presentation, accessible through the conference's recording library. Additionally, Rezolute will conduct 1x1 meetings, available upon request. The company focuses on developing targeted therapies for rare and metabolic diseases, with its lead asset RZ358 in Phase 2b for congenital hyperinsulinism. RZ402 is also set to enter clinical trials for diabetic macular edema.